MSK Cancer Center research advances include proton therapy for leptomeningeal metastasis and evaluating large language models for cancer pain summary.
Key Details
- 1Proton therapy controls leptomeningeal metastasis, with patients living over twice as long versus conventional radiation.
- 2Randomized phase 2 trial: proton craniospinal therapy offers stability >3x longer for LM compared to standard radiation.
- 3Study funded by PCORI explores LLM-based PainReporter model to summarize cancer patient pain experiences from narrative notes.
- 4Research on tumor genetics and location finds SMAD4 reactivation suppresses liver metastases but increases lung metastases.
- 5Regulatory T cells, via enkephalin, regulate pain/inflammation in skin neuronal circuits.
Why It Matters
Advances in radiotherapeutic options like proton therapy improve outcomes in difficult cancer metastasis scenarios. Testing LLMs for summarising patient pain could impact clinical workflow, interpretation, and the integration of AI into patient care.
Source
EurekAlert
Related News
•EurekAlert
New Daydreaming Algorithm Boosts Neural Networks' Recall of Biased Image Data
Researchers unveil a new 'Centered Daydreaming' algorithm enabling AI to effectively learn and recall from imbalanced, real-world image data.
•EurekAlert
Polymer-Based Flexible Wireless Sensors: AI-Driven Health Monitoring Review
A major review highlights how advanced polymer-based flexible wireless sensors, enhanced by AI-driven data processing, can transform continuous physiological health monitoring.
•EurekAlert
PET Imaging Uncovers Synaptic Loss Patterns in Schizophrenia
A major PET imaging study reveals widespread, non-random synaptic loss in schizophrenia, distinct from brain volume changes seen on MRI.